Lynx1 Capital Management LP bought $9.8M of CGEM
owner at Cullinan Therapeutics, Inc.. 1,459,641 shares at an average of $6.73, traded Oct 8, 2025, filed Oct 10, 2025.
Score components
- +12Role10% owner
- +25Trade size$9.8M at market
- +6Relative to holdingsHoldings up 21%
- +8Price context63% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.8%, 3m +47.3%, 6m +96.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000902664-25-004379, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 8, 2025 | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +556,300 | $6.46 | $3.6M | 7,645,743 | Oct 10, 2025 |
| Oct 9, 2025 | POpen-market purchase Common Stockindirect: See footnote | +626,043 | $6.70 | $4.2M | 8,271,786 | Oct 10, 2025 |
| Oct 10, 2025 | POpen-market purchase Common Stockindirect: See footnote | +277,298 | $7.36 | $2.0M | 8,549,084 | Oct 10, 2025 |
Related signals
Other insiders at Cullinan Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $173k 8,000 shares | -5% | |
| 5Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $608k 30,000 shares | -16% | |
| 0Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $143k 8,000 shares | -5% | |
| 0Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $117k 8,000 shares | -5% | |
| 6Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $125k 8,000 shares | -4% | |
| 15Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $25k 1,780 shares | -1% | |
| 52Moderate | Cullinan Therapeutics, Inc. | Nadim Ahmed President and CEO | $196k 13,515 shares | -3% | |
| 37Weak | Cullinan Therapeutics, Inc. | Jacquelyn L Sumer Chief Legal Officer | $52k 3,601 shares | -3% | |
| 38Weak | Cullinan Therapeutics, Inc. | Jeffrey Alan Jones Chief Medical Officer | $66k 4,582 shares | -3% | |
| 18Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $77k 5,353 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.